NEW YORK, NY – As October marks Breast Cancer Awareness Month, the familiar sea of pink ribbons often dominates the public consciousness. However, for a specific segment of the patient population, the narrative of "early detection" and "beating the disease" is not just incomplete—it is often alienating. For those living with metastatic breast cancer (MBC), also known as Stage 4, the battle is not about prevention; it is about survival.
On October 13, National Metastatic Breast Cancer Awareness Day, the nonprofit organization METAvivor is set to transform the global skyline. Through its #LightUpMBC campaign, more than 325 landmarks across 20 countries and all 50 U.S. states will illuminate in the symbolic colors of teal, green, and pink. The initiative serves as a poignant reminder that while advancements have been made, Stage 4 cancer remains a terminal diagnosis for which there is no current cure.
The Reality of Stage 4: Defining the Invisible Struggle
Metastatic breast cancer occurs when cancer cells spread from the primary site in the breast to distant organs, most commonly the bones, liver, lungs, or brain. Despite this migration, the disease is still classified as breast cancer; it is not "lung cancer" or "liver cancer," but breast cancer that has metastasized.
For the patient, this diagnosis is a life-altering event. Some individuals are diagnosed at Stage 4 from the outset (de novo), while others develop metastatic disease months, years, or even decades after completing initial treatment for early-stage breast cancer. The medical reality is daunting: treatment is a lifelong, ongoing process. Even when diagnostic scans show "no evidence of disease" (NED), the condition is not considered cured. Instead, patients exist in a state of perpetual vigilance, undergoing constant therapy to control tumor growth, extend life, and maintain quality of life.
As the cancer inevitably develops resistance to various therapies, patients must transition through a sequence of treatments, each with its own physical and emotional toll. According to data from the National Cancer Institute’s SEER program, an estimated 42,670 people in the United States are projected to die from breast cancer in 2026—a harrowing statistic that translates to roughly 117 lives lost every single day.
A Chronology of Advocacy: From One Landmark to a Global Movement
The #LightUpMBC campaign did not begin in a corporate boardroom, but from a place of profound personal loss. The movement was founded by Laura Inahara, who sought to honor her best friend, Jessica Moore. Moore, who was diagnosed with MBC at a young age, held a simple, poignant wish: to see one local landmark illuminated to raise awareness for the disease that was claiming her life.
Following Moore’s passing at the age of 36, Inahara transformed that grief into a mission. The inaugural lighting took place in 2017 at the Memorial Bridge in Portsmouth, New Hampshire. What began as a singular, local tribute has since snowballed into an international phenomenon.
- 2017: The first #LightUpMBC event occurs at Portsmouth’s Memorial Bridge.
- 2018–2020: The campaign gains momentum, expanding to major U.S. cities and attracting the attention of local governments and private landmark owners.
- 2021–2025: The introduction of the #LightUpMBC Live digital broadcast expands the reach of the campaign, incorporating global patient stories and professional artistic performances.
- 2026: The campaign reaches a new milestone, with over 325 landmarks participating, including global icons like the Willis Tower in Chicago, One World Trade Center in New York, and Niagara Falls.
This growth has not only raised visibility but has also translated into significant financial support. To date, the campaign has raised over $2.7 million, with 100% of net proceeds directed exclusively toward Stage 4 research.
The Science of Survival: Why METAvivor Focuses on Stage 4
A common misconception in the oncology community is that funding for "breast cancer" is distributed equitably. However, the vast majority of research dollars—and public awareness—is historically directed toward early-stage screening and prevention. METAvivor remains the only national organization in the United States that exclusively funds Stage 4 metastatic breast cancer research.
The organization utilizes a rigorous, two-tiered review process. Each grant proposal undergoes a scientific peer review to ensure technical viability and a patient advocate review to ensure that the research is meaningful and relevant to those living with the disease. This focus on "survivability" is the cornerstone of their mission.
"When I was diagnosed with metastatic breast cancer in 2013, I certainly didn’t think I’d still be here 13 years later," says Dr. Kelly Shanahan, Board President of METAvivor. "My hope and the hope of so many others lies in research, and METAvivor-funded research is increasingly important these days. #LightUpMBC is the biggest contributor to this research, and is also a way to bring us together as a community."
LightUpMBC Live: A Multimedia Approach to Awareness
The centerpiece of the awareness day is the #LightUpMBC Live broadcast, a free, globally accessible event scheduled for October 13 at 8 p.m. ET / 5 p.m. PT. Hosted by Tami Eagle Bowling—a 11-year MBC survivor—and Broadway star Kara Lindsay, the broadcast is designed to bridge the gap between clinical data and the human experience.
The program promises a multifaceted look at the disease:
- Patient Narratives: Real-time stories shared from the bases of illuminated landmarks, highlighting the daily challenges and triumphs of patients.
- Scientific Perspectives: Leading researchers will provide updates on emerging therapies and the quest for a cure.
- Artistic Tributes: The broadcast will feature performances by two-time Tony Award winner Victoria Clark, Tony Award nominee Dorian Harewood, actress Christina Bianco, and songwriter Cassandra Kubinski.
The event will be streamed across multiple platforms, including the METAvivor YouTube channel, Facebook Live, and the LiveOne network, ensuring that the message of hope and the call to action reach a global audience.
The Implications: Why Awareness Must Lead to Action
The overarching goal of #LightUpMBC is to shift the narrative. By illuminating iconic structures in teal, green, and pink, the campaign forces a conversation that many would prefer to avoid. It challenges the "pink-washing" of breast cancer, which often glosses over the reality of terminal illness.
The implications of this campaign are three-fold:
- Fundraising: The direct financial impact allows for the acceleration of innovative research that would otherwise remain unfunded.
- Patient Empowerment: By providing a platform for patient voices, the campaign equips those living with the disease with the tools and community support necessary to navigate their own treatment paths.
- Societal Education: By moving the needle on public understanding, the campaign hopes to destigmatize the disease and encourage broader support for long-term, chronic care solutions.
As Laura Inahara reflects on the legacy of her friend, the message is clear: "Jessica hoped to illuminate one local landmark. Today, her legacy helps families around the world shine a light for the people they love, teach patients with MBC how to advocate for themselves, and has now raised over $2.7 million for critical MBC research."
Join the Movement
On October 13, the public is encouraged to participate in this global act of solidarity. Whether by visiting a local landmark, capturing a photograph, or sharing stories on social media with the tags #LightUpMBC and #METAvivor, every action contributes to the momentum of the movement.
For those looking to make a direct impact, donations can be made through the official website, www.lightupmbc.org. The site also provides a full list of participating landmarks and links to the live stream. In a world that often looks away from the terminal nature of Stage 4 cancer, #LightUpMBC serves as an essential reminder that as long as there is a light, there is hope—and as long as there is hope, there is a reason to keep fighting.
About the Author
